Tag: ATX

Amplia Therapeutics ASX ATX Phase 2 AMP945 trial treat advanced pancreatic cancer

Amplia Therapeutics completes design of phase 2 AMP945 trial to treat advanced pancreatic cancer

Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) has completed the design for a phase 2 clinical trial of its focal adhesion kinase (FAK) inhibitor AMP945 for the treatment of advanced...
Amplia Therapeutics ASX ATX cancer fibrosis AMP945 small molecule focal adhesion kinase FAK inhibitor program

Amplia Therapeutics prepares for phase two AMP945 trial backed by shareholders

Amplia Therapeutics (ASX: ATX) will be spending the September quarter finalising the design of phase two clinical trials of its lead drug AMP945 in both pancreatic cancer and idiopathic lung fibrosis ...
Amplia Therapeutics ASX ATX Phase 1 clinical trial AMP945 cancer fibrosis

Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has announced the unblinded results of a phase one clinical trial that supports further development of its drug AMP945 in cancer and fibrosis. ...
Amplia Therapeutics ASX ATX Garvan Institute pancreatic cancer drug

Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has finalised a deal with the Garvan Institute of Medical Research in Sydney to collaborate on the development of Amplia’s drug AMP945 to treat pa...
Amplia Therapeutics ASX ATX FDA Orphan Drug Designation Idiopathic Pulmonary Fibrosis

Amplia Therapeutics receives second orphan drug designation for treatment of chronic lung disease

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has received a second orphan drug designation from the US Food and Drug Administration for its focal adhesion kinase inhibitor AMP945. The desi...
Amplia Therapeutics ASX ATX FDA Amplia orphan drug designation pancreatic cancer

Amplia Therapeutics receives FDA orphan drug designation for pancreatic cancer

Pharmaceutical company Amplia Therapeutics (ASX: ATX) has received regulatory approval from the US Food and Drug Administration (FDA) for its Focal Adhesion Kinase inhibitor (FAKi) AMP945 – a novel ne...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS